Immunotherapy: Is it different for sarcomas?

The Janus-faced roles of macrophages in cancer imply both tumor-suppressive and -stimulating actions of these innate immune cells. Whereas the balance is toward tumor promotion in most epithelial cancers, we have recently shown that osteosarcoma metastasis seems to be inhibited by macrophages. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Cleton-Jansen, Anne-Marie, Buddingh, Emilie P., Lankester, Arjan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376989/
https://www.ncbi.nlm.nih.gov/pubmed/22720262
http://dx.doi.org/10.4161/onci.1.2.18345
_version_ 1782235897250447360
author Cleton-Jansen, Anne-Marie
Buddingh, Emilie P.
Lankester, Arjan C.
author_facet Cleton-Jansen, Anne-Marie
Buddingh, Emilie P.
Lankester, Arjan C.
author_sort Cleton-Jansen, Anne-Marie
collection PubMed
description The Janus-faced roles of macrophages in cancer imply both tumor-suppressive and -stimulating actions of these innate immune cells. Whereas the balance is toward tumor promotion in most epithelial cancers, we have recently shown that osteosarcoma metastasis seems to be inhibited by macrophages. Here we discuss the possible mechanism of this observation.
format Online
Article
Text
id pubmed-3376989
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-33769892012-06-20 Immunotherapy: Is it different for sarcomas? Cleton-Jansen, Anne-Marie Buddingh, Emilie P. Lankester, Arjan C. Oncoimmunology Author's View The Janus-faced roles of macrophages in cancer imply both tumor-suppressive and -stimulating actions of these innate immune cells. Whereas the balance is toward tumor promotion in most epithelial cancers, we have recently shown that osteosarcoma metastasis seems to be inhibited by macrophages. Here we discuss the possible mechanism of this observation. Landes Bioscience 2012-03-01 /pmc/articles/PMC3376989/ /pubmed/22720262 http://dx.doi.org/10.4161/onci.1.2.18345 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Cleton-Jansen, Anne-Marie
Buddingh, Emilie P.
Lankester, Arjan C.
Immunotherapy: Is it different for sarcomas?
title Immunotherapy: Is it different for sarcomas?
title_full Immunotherapy: Is it different for sarcomas?
title_fullStr Immunotherapy: Is it different for sarcomas?
title_full_unstemmed Immunotherapy: Is it different for sarcomas?
title_short Immunotherapy: Is it different for sarcomas?
title_sort immunotherapy: is it different for sarcomas?
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376989/
https://www.ncbi.nlm.nih.gov/pubmed/22720262
http://dx.doi.org/10.4161/onci.1.2.18345
work_keys_str_mv AT cletonjansenannemarie immunotherapyisitdifferentforsarcomas
AT buddinghemiliep immunotherapyisitdifferentforsarcomas
AT lankesterarjanc immunotherapyisitdifferentforsarcomas

Ejemplares similares